With clinical data in hand, trio of Bay Area biotechs raise collective $1.1 billion

The companies are pushing forward against fibrosis in fatty liver disease, to stop a dangerous kidney condition or to prevent pneumonia, and their latest news was rewarded by Wall Street investors.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertisement — Advertise with Biotech Networks